JAK2抑制剂获批7年后在骨髓增殖性肿瘤中的作用
骨髓增殖性肿瘤(MPN)包括原发性血小板增多症、真性红细胞增多症(PV)和原发性骨髓纤维化(MF),JAK2/STAT通路是关键信号级联。JAK2抑制剂芦可替尼(RUX)已获批用于中高危MF及羟基脲控制不佳或不耐受的PV,在晚期MF中约60%患者达到持续脾体积应答(SVR)>35%,在PV中约60%病例达到血细胞比容控制、40%达到SVR。长期随访中许多MF患者失去SVR,RUX失败的定义及新试验设计仍是未满足的需求。
要点
- 芦可替尼(RUX)获批用于中高危MF及羟基脲控制不佳或不耐受的PV。
- 晚期MF中约60%患者达到持续SVR>35%,PV中约60%达到血细胞比容控制。
- RUX常见不良反应为血红蛋白/血小板下降和感染率增加,需监测非黑色素瘤皮肤肿瘤。
核心结论
- JAK2抑制剂(芦可替尼、fedratinib、pacritinib)的引入提高了MF和PV的治疗目标标准。
- 长期随访中许多MF患者失去SVR,RUX失败的定义及该情况下新试验的设计仍是未满足的需求。
研究设计与样本
- 本文为综述,围绕JAK2抑制剂获批7年后在骨髓增殖性肿瘤(MPN)中的作用进行总结。
- MPN包括原发性血小板增多症、真性红细胞增多症(PV)和原发性骨髓纤维化(MF)。
- JAK2、CALR和MPL基因的表型驱动突变存在于MPN中,可与其他附加突变以不同方式组合。
主要发现
- 驱动突变导致JAK2/STAT通路组成性激活,该通路是MPN中的关键信号级联。
- 在晚期MF中,RUX在约60%的患者中达到持续>35%的脾体积应答(SVR),为MF治疗建立了新的基准。
- RUX在早期MF中疗效也显著且毒性轻微。
- 在PV中,RUX在约60%的病例中达到血细胞比容控制,在40%中达到SVR。
- 两种疾病中症状缓解均明显。
关键数值与推荐
- MF试验的主要终点为脾体积应答(SVR)和症状应答。
- PV试验的主要终点为血细胞比容控制,伴或不伴脾应答。
- 芦可替尼(RUX)已获批用于中危和高危MF的治疗,以及羟基脲控制不佳或不耐受的PV。
- fedratinib和pacritinib等其他JAK2抑制剂在MF中证明有用。
- RUX最常见的副作用为血红蛋白/血小板水平下降和感染率增加,治疗期间需监测非黑色素瘤皮肤肿瘤。
临床怎么用
- 原文未据此给出推荐。
局限性
- 长期随访中许多MF患者失去SVR。
- RUX失败的定义及该情况下新试验的设计仍是未满足的需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myeloproliferative neoplasms (MPNs) include essential thrombocythemia, polycythemia vera (PV), and primary myelofibrosis (MF). Phenotype-driver mutations of JAK2, CALR, and MPL genes are present in MPNs and can be variably combined with additional mutations. Driver mutations entail a constitutive activation of the JAK2/STAT pathway, the key signaling cascade in MPNs. Among JAK2 inhibitors (JAKis), ruxolitinib (RUX) has been approved for the treatment of intermediate and high-risk MF and for PV inadequately controlled by or intolerant of hydroxyurea. Other JAKis, such as fedratinib and pacritinib, proved to be useful in MF. The primary end points in MF trials were spleen volume response (SVR) and symptom response, whereas in PV trials they were hematocrit control with or without spleen response. In advanced MF, RUX achieved a long lasting SVR of >35% in ∼60% of patients, establishing a new benchmark for MF treatment. RUX efficacy in early MF is also remarkable and toxicity is mild. In PV, RUX achieved hematocrit control in ∼60% of cases and SVR in 40%. Symptom relief was evident in both conditions. In the long-term, however, many MF patients lose their SVR. Indeed, the definition of RUX failure and the design of new trials in this setting are unmet needs. Decrease of hemoglobin/platelet levels and increased infection rates are the most common side effects of RUX, and nonmelanoma skin tumors need to be monitored while on treatment. In conclusion, the introduction of JAKis raises the bar of treatment goals in MF and PV.
引用
- Passamonti F, Maffioli M. The role of JAK2 inhibitors in MPNs 7 years after approval. Blood. 2018. PMID: 29650801. doi:10.1182/blood-2018-01-791491
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。